芪藶強(qiáng)心膠囊聯(lián)合達(dá)格列凈治療射血分?jǐn)?shù)減低型心力衰竭的效果及預(yù)后

打開文本圖片集

The Effect and Prognosis of Qili Qiangxin Capsules Combined with Dapagliflozin in the Treatment of Heart Failure with Reduced Ejection Fraction/XU Wang，LUO Gang，LIANG Huiying.//Medical Innovation of China，2025，22（18）：036-040

[Abstract]Objective： To investigate the effcacy and prognosis of Qili Qiangxin Capsules combined with Dapagliflozin in the treatmentof heart failure with reduced ejection fraction （HFrEF）.Method：A total of 84 patients with HFrEF admited to Ganzhou People's Hospitalfrom May2O22 to August 2023 were randomlydivided into two groups of 42 each using arandom number table method.The control group was treated with Dapagliflozin， while the experimental group was treated with Qili Qiangxin Capsules combined with Dapagliflozin.The efficacy， myocardial marker levels，exercise endurance，ventricular remodeling indicators，adverse reactions，and prognosis between two groups werecompared.Result： The total effective rate of treatment in the experimental group was higher thanthatof thecontrol group（ P <0.05）;cardiac troponin （cTnI），N-terminal pro-brainnatriuretic peptide （pro-BNP），left ventricular end diastolic diameter （LVEDD）and left ventricular end systolic diameter （LVESD） in theexperimental group were lower than those in thecontrol group after6 months of treatment，the 6-minute walk test（6MWT）and left ventricular ejection fraction （LVEF） were higher than thoseof the control group （ P <0.05）. There was no statistically significant diference in the incidence of adverse reactions between the two groups （ P2 0.05）; the incidence of poor prognosis in the experimental group was lowerthan that in the control group （ P <0.05）.

Conclusion： Thecombination of Qili Qiangxin Capsules and Dapagliflozin has a good therapeutic efect on HFrEF， which can reduce myocardial marker levels，improve exercise endurance，inhibit ventricular remodeling，improve prognosis，and has good safety.

[Key words]Heart failure with reduced ejection fraction Qili Qiangxin CapsulesDapagliflozin Prognosis

First-author'saddress：Departmentof Cardiovascular Medicine，Ganzhou People'sHospital， Ganzhou 41000，China

doi：10.3969/j.issn.1674-4985.2025.18.009

射血分?jǐn)?shù)減低型心力衰竭（HFrEF）作為慢性心力衰竭常見類型，其病因復(fù)雜，多認(rèn)為與過度勞累、呼吸道感染等有關(guān)，會導(dǎo)致心排血量降低，體循環(huán)靜脈瘀血，嚴(yán)重會造成全身動脈灌注不足，引發(fā)猝死、惡性心律失常等，威脅患者生命安全[]。（剩余6380字）